Arena Pharmaceuticals Highlights Strategic Plan Driving Near and Long-term Growth with Eight Ph 2 and Ph 3 Data Readouts in 2020-21 and One New IND Per Year for the Next 5 Years

- Initiation of etrasimod Ph 2/3 program in Crohn's disease (CD)

- Two additional Ph 2 etrasimod development programs in eosinophilic esophagitis (EoE) and alopecia areata (AA)

-  First subject dosed in APD418 Ph 1 trial in Decompensated Heart Failure (DHF)

-  Expanded multi-program collaboration with Beacon Discovery for immune and inflammatory targets (Project Cabrillo)

-   Formation of Arena Neuroscience, Inc. focused on programs and platform to address microglial neuroinflammation

-  Arena to host conference call and webcast tomorrow, January 7, at 9:00 AM ET

SAN DIEGO, Jan. 6, 2020 /PRNewswire/ --Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will provide a corporate update highlighting its strategic portfolio expansion on a conference call tomorrow, January 7, at 9:00 AM ET, and provide additional detail at the 38th Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2020.

"Arena had a stellar year in 2019, starting with the closing of the landmark ralinepag deal with United Therapeutics, and successfully initiating multiple important Phase 2 and 3 trials across our portfolio," stated Amit D. Munshi, President and Chief Executive Officer of Arena. "Building upon our success in 2019, we are preparing for future growth with an expanded pipeline including two new indications for etrasimod, an expanded collaboration with Beacon Discovery - Project Cabrillo - focused on new immunology and inflammation targets, and a new wholly owned subsidiary, Arena Neuroscience, Inc., that will focus on programs and platform to address microglial neuroinflammation. Arena is poised to build a bold, vibrant, catalyst-rich company over the next decade as we focus on the delivery of multiple important medicines."

Growth Drivers:
Clinical Pipeline

• Etrasimod in development for five gastrointestinal and dermatologic indications targeting approximately $48B market opportunity
• Ongoing Ph 3 program in ulcerative colitis (UC)
• Ongoing Ph 2b data in atopic dermatitis (AD)
• Initiation of Crohn's disease (CD) Ph 2/3 program
• New Ph 2b program in eosinophilic esophagitis (EoE)
• New Ph 2 program in alopecia areata (AA)
• Olorinab
• Ongoing Ph 2b data in abdominal pain associated with irritable bowel syndrome (IBS-C, IBS-D)
• APD418
• Ongoing Ph 1 trial in decompensated heart failure (DHF)

Emerging Franchises